



STRATEGIC
PHARMA
INCORPORATED

Today's Research Tomorrow's Solutions

November 19, 2016

Our Speaker

Jenalee Alexander

Vice President of Marketing

SPI Vice President of Marketing Jenalee Alexander is an expert in communication solutions. Her passion for improving the lives of others emboldened her in pursuit towards a career in the clinical research industry.

jenalee.alexander@strategicpharmainc.com





STRATEGIC
PHARMA
INCORPORATED

1

What We Do and Why We Do it

People Matter

**At SPI, we focus on people first—
ensuring that our research seeks
the best outcomes for people
suffering with life altering ailments.**





STRATEGIC
PHARMA
INCORPORATED

2

Framing the Opportunities

Few Formal Trials

Less than 100 trials have been run since 1985 targeting the CB1 and CB2 receptors.


- What are they?
- How do they relate to cannabis?



Defining Cannabinoids

There have been 545 natural components identified in Cannabis, of those, 104 are cannabinoids.

- Diverse chemical compounds
- Act on receptors altering neurotransmissions
- THC and CBD



Broad Potential

Cannabis/Hemp extracts have been reported to treat as many as 87 different disease indications

- SPI is researching indications of 54

Over 50% of drugs approved in the last 30 years derived from *Natural Products*

- Aspirin, Morphine, Taxol, Penicillin



Safety in Science

Cannabis is Safe.

- Clinical studies with CBD/THC have demonstrated the compounds are well tolerated with no side effects
- No side events have been detected with CBD doses as high as 100 mg/kg





STRATEGIC
PHARMA
INCORPORATED


3

The SPI Impact

Over the Counter Pain Relief

No effect on bleeding time:


- Validation against Aspirin
- Does not thin blood
- More effective in treating pain



More effective than Ibuprofen

CBD 10x more effective at treating chronic pain than Ibuprofen


- Ibuprofen causes GI bleeding– why?
- CBD does not cause GI bleeding
- There are no proven side effects of CBD



Replacing Opioids

CB1 receptor agonists (Cannabis) proves to be more effective than opioids in suppressing neuropathic pain


- Validation with Morphine (post-surgical)
- Ability to achieve analgesia with 5x lower morphine
- Retain effectiveness over a longer period of time
- Fewer opioids, less risk



Replacing Opioids

Proven effective supplement for neuropathic pain relief:

- Validation against Gabapentin
- CBD has a longer extent of pain relief



THC/CBD Research & Beyond

SPI is poised to create solutions for ailments over the course of the next year:


- **Pain** - Oct. 2016
- **Epilepsy** - Dec. 2016
- **Anxiety** - Feb. 2017
- **TBI/CTE** - May 2017
- **Sleep** - July 2017
- **Depression** - Aug. 2017
- **Psychosis** - Sept. 2017
- **PTSD** - Dec. 2017



Prescription Drugs

The CDC has reported the following in states with legalized marijuana:

- 25% fewer opioid deaths
- 28-25% reduction in addiction admissions
- 1,826 fewer prescription painkiller doses
- Over \$178.5 million in Medicaid savings



Opioid Epidemic

- Opioids killed over 28,000 people in 2014.
- At least half involved prescriptions
- Rx opioid sales have quadrupled since 1999
- More than 165,000 people have died since



The Detriment of PTSD

- 22 veterans take their own life every day
- That number is actually higher
- 30% of all veterans have considered
- 30 veterans per 100,000 population
- Nearly double the civilian suicide rate





STRATEGIC
PHARMA
INCORPORATED

3

How We Can Do What We Do

Unprecedented Licensure


Our DEA Schedule 1 License, MED Occupational License, and Medical Cannabis Testing License allow us to find the optimum pure doses of THC and CBD.

As a result, SPI can fully test all strains and extract compositions available in the highest quality organic hemp and marijuana.



Optimized Facilities

Our facilities are custom built for optimal neuroscience research. We can compare our research results side by side with products currently on the market through a clinically relevant process.



Quality Control

Each batch tested for:

- Cannabinoid content, heavy metals, residual solvent, pesticides, fertilizers and microbial
- **No raw material enters manufacturing until passes tests**
- **Tablets verified through GMP manufacture to be at least 25 mg CBD**



Efficient Focus

Our focus on the central and peripheral nervous systems allows us to determine the best courses of action without wasting time on distractions.



Clinically Relevant Testing

We use clinically relevant, validated tests to aid in creating precisely-defined and designed products that target a variety of ailments while emphasizing better results.



Comprehensive Research Analytics

—
Our comprehensive research analytics meet the high standards used and required in the pharmaceutical industry. We can provide in-depth information to clients and the people they help.

- Matching Strain with Indication
- Identifying Relevant Biomarkers
- Connecting Biomarkers and Strain



Expedited Time to Market

Our efficiency, team of experts, and capacities enable us to get products to market quickly. On average, we have the ability to move products forward in as little as nine months vs. the traditional standard of 6–10 years.



SPI Leadership

Ours is a team of unique experts elevating cannabis with extensive experience in:

- Executive leadership
- Entrepreneurialism
- Leading public and private equity initiatives
- Pre-clinical and early stage clinical development
- Hands-on drug development
- Clinical research
- Clinical operations
- Laboratory operations
- In-vivo neuropharmacology
- Pain and drugs of abuse
- Phase work management



Christopher Meredith, EdD
CEO/Founder



Dan Menard, PhD, PsyT
Executive Vice President of
Research & Development



Kirsten Raehal, PhD
Senior Scientist



Andy Cooke, PhD
Senior Director of Scientific
Operations



STRATEGIC
PHARMA
INCORPORATED

4 | Questions?



STRATEGIC
PHARMA
INCORPORATED

Thank You

November 19, 2016